Episurf Medical achieved a milestone of 100 accounts approved and connected to the company’s proprietary μifidelity™ IT platform, used with Episealer® personalized implants and Epiguide® drill guides to treat localized joint cartilage injury.
μiFidelity is designed to support implants that may be cost-efficiently tailored to individual injuries for optimal fit with minimal intervention.
During 2016, the company will continue activities to expand sales in Germany and the U.K.
Source: Episurf Medical AB
Episurf’s first product, Episealer® Femoral Condyle, received CE Mark approval in 3Q13, and sales subsidiaries were established in 2Q15. For 3Q15, the company reported sales of SEK 150,174 (~US $17,380), +91.9% vs. 3Q14, and YTD 2015 sales of SEK 641,094 (~$74,200), +441% vs. the prior year.
Episurf Medical achieved a milestone of 100 accounts approved and connected to the company's proprietary μifidelity™ IT platform, used with Episealer® personalized implants and Epiguide® drill guides to treat localized joint cartilage injury.
μiFidelity is designed to support implants that may be cost-efficiently tailored to individual...
Episurf Medical achieved a milestone of 100 accounts approved and connected to the company’s proprietary μifidelity™ IT platform, used with Episealer® personalized implants and Epiguide® drill guides to treat localized joint cartilage injury.
μiFidelity is designed to support implants that may be cost-efficiently tailored to individual injuries for optimal fit with minimal intervention.
During 2016, the company will continue activities to expand sales in Germany and the U.K.
Source: Episurf Medical AB
Episurf’s first product, Episealer® Femoral Condyle, received CE Mark approval in 3Q13, and sales subsidiaries were established in 2Q15. For 3Q15, the company reported sales of SEK 150,174 (~US $17,380), +91.9% vs. 3Q14, and YTD 2015 sales of SEK 641,094 (~$74,200), +441% vs. the prior year.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





